Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
Patients with nonalcoholic fatty liver disease (NAFLD) may develop significant fibrosis in the absence of nonalcoholic steatohepatitis (NASH), with risk factors including fasting hyperglycaemia, severe steatosis, mild inflammation and the PNPLA3 I148M variant, according to a recent study.
Use of statins appears to reduce the risk of developing hepatocellular carcinoma in patients with nonalcoholic fattly liver disease (NAFLD), whereas hypertension conferred a risk increase, according to a retrospective case-control study.
The trend in liver disease-related mortality in individuals with HIV has changed, with a reduction in the incidence of viral hepatitis-related deaths and an increase in non-alcoholic fatty liver disease (NAFLD)-related deaths, according to a study presented at the International Liver Congress™ (ILC 2019).
Patients with non-alcoholic steatohepatitis (NASH) may benefit from treatment with a 25 mg/day dose of obeticholic acid, according to the interim analysis of the phase III REGENERATE* study presented at the International Liver Congress™ (ILC 2019).
Adults with non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH) who progress to advanced liver disease have an elevated risk of mortality compared with non-progressors, according to two separate studies conducted in Germany and France and presented at the International Liver Congress™ (ILC 2019).
Individuals with imaging-defined or biopsy-proven nonalcoholic fatty liver disease are likely to have a self‐reported history of osteoporotic fractures but not a low bone mineral density, according to a meta-analysis.
The patient profiles of individuals diagnosed with hepatocellular carcinoma (HCC) vary depending on whether the cause of HCC is hepatitis B virus (HBV) infection or cryptogenic, a Singapore study found.
Complete resolution of nonalcoholic fatty liver disease (NAFLD) is highly likely to occur following sustained weight loss in obese patients who have undergone bariatric surgery, although there are still some who may develop new or worsened features of NAFLD, a study has shown.
Updates from the SECURE-IBD* registry reveal that treatment with thiopurine, either alone or in combination with tumour necrosis factor inhibitors (TNFis), for inflammatory bowel disease (IBD) was associated with a greater risk of severe COVID-19 compared with TNFis monotherapy.